Back to catalogue
№ 344 22 filings · 2021-09-02 → 2026-07-20

PULSAR GROUP PLC

PULS
Technology Share price 14.50p Market cap £20m Overall fit 560 /1000

Genuine vertical-SaaS operating leverage and AI-native product refresh at a distressed valuation (2.4x FY25 Adjusted EBITDA) create an interesting risk/reward, but low underlying growth, weak cash conversion and modest balance-sheet leverage keep it out of the top band.

Fair value range 25p–45p Mid case · £47m
Absolute upside +139.1% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Consistent Adjusted EBITDA delivery vs guidance
  • Detailed segmental and ARR disclosure
  • Multi-method valuation converges on similar equity range
Limits the call
  • Recurring 'non-recurring' costs undermine Adjusted EBITDA quality
  • APAC growth trajectory still unproven post-Isentia
Methodology

EV/Adjusted-EBITDA blended with normalised-cash-earnings cross-check

In one line · bull case

Cheap AI-native vertical SaaS with clear operating leverage and 97% recurring revenue, trading at ~2.4x Adjusted EBITDA — priced for permanent stagnation but with optionality on AI upsell delivering an inflection.

In one line · biggest risk

Reported Adjusted EBITDA overstates real cash generation after capitalised development and perpetual 'non-recurring' restructuring, and underlying ARR growth is barely positive.

Drivers
AI beneficiary 58 /100
Vertical SaaS building AI-native agentic products (Lumina, Saga, TeamMates) for PR/comms — beneficiary of AI-per-seat monetisation, but no clear revenue-line uplift disclosed yet.
Operating leverage 72 /100
97% recurring revenue, 65% gross margin, largely fixed £16m recurring admin cost — H1 2026 delivered 48% incremental EBITDA margin on new revenue.
Earnings vs expectations 58 /100
Consistent in-line or modest-beat on Adjusted EBITDA across five years, but revenue guidance has been trimmed twice.
Growth momentum 38 /100
Constant-currency ARR growth just £1.2m (~1.9%) in H1 2026 — reported 10% revenue growth is mostly FX.
Moat 40 /100
Some switching costs and data-integration stickiness but a crowded market with Cision, Meltwater and Brandwatch as scaled competitors.
Earnings quality 38 /100
£6m/yr capitalised dev and recurring 'non-recurring' restructuring costs (£8-10m/yr) mean statutory losses persist while Adjusted EBITDA looks healthy.
Management quality 55 /100
Delivered Isentia integration and £7m cost-out on schedule; capital allocation reasonable but Isentia acquisition price (AUD$80m gross) has been slow to justify.
Cyclicality 45 /100
Subscription revenue is defensive but marketing budgets are cyclical — management flagged 'constrained marketing budgets' in H1 2026.
Leverage 40 /100
£6m net debt on £10m Adjusted EBITDA; refinanced April 2026 with 3yr HSBC facility — manageable but not fortress.
Value-trap signals · 5
  • 'Non-recurring' costs recurring every year of the five-year window
  • Statutory losses every year despite positive Adjusted EBITDA
  • £6m/yr of capitalised development inflating Adjusted EBITDA vs cash
  • APAC ARR still declining on constant-currency basis in H1 2026
  • Share price down ~60% in 12 months with no clear operational break

Pulsar Group PLC (AIM: PULS) — Investment Research Note

Executive summary

Pulsar Group is an AIM-listed audience-intelligence SaaS business selling media monitoring, social listening and AI-driven insights software to PR, communications and marketing teams across EMEA/NA and APAC, with £67.2m of ARR and c.6,000 customers. Over the five-year filings period the story has moved from a costly Isentia acquisition in APAC (Sept 2021) through a multi-year integration, restructuring and rebrand to a business that is now, in H1 FY26, delivering 10% revenue growth, 39% Adjusted EBITDA growth (£3.6m→£5.1m) and improving cash generation — but at the price of persistent statutory losses, heavy capitalised development and a sharp de-rating (from 48.5p to 19p in the last twelve months). The single most important valuation point today is that the market is capitalising a mid-cap-quality SaaS business (£61m revenue, £10.4m Adjusted EBITDA, 97% recurring) at only ~£25m — well below any credible multiple even after conservatively adjusting Adjusted EBITDA for capitalised dev and recurring "non-recurring" costs.

Fair value estimate

  • Fair value range: 25p – 45p per share (implied market cap £34m – £61m).
  • Methodology: Blended EV/Adjusted-EBITDA and normalised-cash-earnings check.
    • FY26E Adjusted EBITDA of ~£11–12m (guidance "in line", with continued cost-base reductions flagged) at a 4–6x EV/EBITDA multiple (discounted vs peers for cash-quality issues and slow ARR growth): EV £44–72m, less £6m net debt → equity £38–66m.
    • Cross-check: true "cash EBITDA" after capitalised dev (£5–6m/yr) and recurring "non-recurring" restructuring (£2–3m/yr steady-state) is closer to £3–5m. At 10–12x that gives £30–60m equity, consistent with the multiple approach.
  • Comparison to £25.1m market cap: midpoint implied equity of ~£47m ⇒ ~85% upside to 35p mid; range spans +32% to +137% vs 19p spot market data 2026-09-23, 2026-07 interim, 2026-05 final.

Sector context

Classification confirmed: Technology / Software (vertical SaaS). On quality metrics — 65-69% gross margin, 97% recurring revenue, ~£67m ARR — the business is broadly in line with sector norms; growth momentum (mid-single digit constant-currency ARR) is below typical SaaS peers, and balance-sheet leverage (£6m net debt on £10m EBITDA) is modestly above peer median. Nearest listed comparables: Cision (private/PE-owned), Meltwater (Oslo — taken private by AGM 2024), Brandwatch (part of Cision), and larger vertical MarTech names like Sprinklr, Klaviyo and UK-listed GlobalData. Given the depth of the peer set that's already been consolidated by PE, PULS itself is a plausible M&A target.

Investment thesis

  • Cheap AI-native vertical SaaS with genuine operating leverage. Adjusted EBITDA rose 39% on 10% revenue growth in H1 2026, and management has already stripped £7m of annualised cost with further reductions flagged for H2 FY26. On £61m revenue and £16m recurring admin cost, incremental ARR at ~65% GM drops disproportionately to EBITDA 2026-07 interim; 2026-05 final.
  • Trading at 2.4x FY25 Adjusted EBITDA / 0.4x sales despite 97% recurring revenue, blue-chip customer wins (Apple, Microsoft, Diageo, Coca-Cola, H&M, Adani, World Bank, Manchester United), and stable ARR base of £67m — a valuation that requires very little of the AI bull case to work 2026-07 interim; 2026-05 final.
  • AI product refresh (Lumina, Saga, Narratives AI, Crisis Oracle, CLEAR, TeamMates agentic framework) creates upsell surface — the CEO frames PR/comms as a category where AI agents raise value-per-seat rather than substitute for the customer, positioning PULS as an AI beneficiary rather than victim 2026-05 final chairman's statement; 2026-02 trading update.

Key risks

  • Slow underlying growth — ARR grew only £1.2m constant currency in H1 2026 (~1.9% annualised). Reported revenue growth of 10% is largely a foreign-exchange tailwind on AUD/USD; APAC ARR was down £0.2m constant currency. If AI products don't drive an inflection, this remains a low-growth, ex-growth SaaS 2026-07 interim.
  • Cash-quality concerns. FY25 statutory loss £9.6m; capitalised development £6m/yr; "non-recurring" restructuring costs have appeared every year for five years (£8.6m FY24, £9.6m FY25). Adjusted EBITDA of £10.4m converts to statutory operating loss of £8.3m — the reader should not take the "5.1m H1 EBITDA" at face value. On a fully-loaded basis the business only turned modestly cash-positive in H1 2026 2026-05 final; 2026-07 interim.
  • Small AIM cap with £6m net debt and covenanted HSBC facility. £1.5m cash at May 2026; only refinanced in April 2026. Any renewed macro or marketing-budget shock (management flags "constrained marketing budgets" in H1 2026) could quickly pressure the balance sheet 2026-07 interim; 2026-05 final going-concern note.

Operating leverage

Operating leverage is one of the more attractive features of this name. On a cost stack of £11.5m COGS, £16.4m recurring admin and £2.7m capitalised dev in H1 2026, the vast majority of admin (people, hosting, data feeds) is fixed. Gross margin is 65% and management has quantified an incremental £7m annualised saving already banked plus further reductions targeted before FY26 year-end. H1 2026 demonstrated the mechanic in practice: £2.9m of reported revenue growth translated into £1.4m of Adjusted EBITDA growth — a 48% incremental EBITDA margin, materially above the group average of 15% 2026-07 interim. Extrapolating: a 10-20% revenue beat above management's central case (~£6-12m of extra revenue) at ~45% incremental margin would add £3–5m to EBITDA (i.e. 30–50% uplift to reported Adjusted EBITDA of ~£11m) — meaningful, but not the "multiple of profit" that a pure fixed-cost network-effect platform would deliver, because a portion of enterprise sales still requires proportional sales/CS resource. The inflection point is capacity utilisation of the current 710-FTE base and the extent to which the Lumina/Saga agentic products deliver seat-monetisation without headcount 2026-05 final.

Value-trap signals

  • Repeated "non-recurring" costs every year of the filings window (£8.6m FY24, £9.6m FY25) — recurring one-offs are a value-trap classic.
  • Statutory losses in every year of the filings window (FY22 -£4.2m, FY23 -£7.9m, FY24 -£6.6m, FY25 -£9.6m) despite Adjusted EBITDA of £2.3m-£10.4m.
  • Heavy capitalised development (~£6m/yr) sustains Adjusted EBITDA optics but the amortisation catches up in later years.
  • APAC ARR still down constant currency in H1 2026 despite the AI product refresh — the "turnaround" is not yet demonstrably real in the region that made up half the business.
  • Multi-year share price decline (48.5p → 19p in 12m) with no clear operational deterioration suggests the market is questioning either the earnings quality or the growth outlook.
  • No dividend cuts, no going-concern qualification, no related-party red flags, no customer concentration (>10% single customer stated absent).

Earnings vs. expectations

Across the filings period, PULS has generally met or modestly beaten its own Board expectations while showing improving momentum:

  • FY22: Adjusted EBITDA £2.3m — trading in line, £4.9m cash 2022-12 trading update.
  • FY23: Adjusted EBITDA £7.3m — the January 2024 trading update said "slightly ahead of consensus" of £6.7m; delivered 2024-01 trading update; 2024-05 final.
  • FY24: Adjusted EBITDA £9.3m — in line with £9.2m FX-adjusted consensus, described as "in line" 2025-01 trading update; 2025-05 final.
  • FY25: Adjusted EBITDA £10.4m — described as "in line with the Board's expectations" 2026-05 final; 2026-02 trading update.
  • H1 FY26: "in line with the Board's expectations" — no consensus references disclosed 2026-07 interim.

Pattern: consistent meet/modest-beat on Adjusted EBITDA, but revenue guidance is less clear, and management has repeatedly guided down revenue expectations (Jan 2022 trading update explicitly cut FY22 revenue outlook due to SEA weakness).

Conviction

Conviction: 3 (moderate).

  • Anchors: disclosure is above AIM average (segmental splits, ARR bridges, non-recurring breakouts, sensitivity analysis in impairment testing); the primary valuation multiple approach fits a subscription SaaS business well; both EBITDA-multiple and normalised-cash approaches converge on a similar equity range.
  • Limits: Adjusted EBITDA is a soft number given the persistent "non-recurring" costs and £6m/yr of capitalised dev; APAC growth trajectory is genuinely uncertain and represents ~half the business; UK-listed AI-marketing peers are almost all private, so multiples are triangulated rather than directly observable.
Filings consulted · 27

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-20Interim Results2026-07-20_9675770_interim-results.md0.90
  2. 2026-05-07Posting OF Annual Report And Notice OF Agm2026-05-07_9557637_posting-of-annual-report-and-notice-of-agm.md0.95
  3. 2026-05-01Final Results For The Year Ended 30 November 20252026-05-01_9547975_final-results-for-the-year-ended-30-november-2025.md1.00
  4. 2026-02-20Trading Update2026-02-20_9439230_trading-update.md0.72
  5. 2025-07-14Interim Results2025-07-14_8976634_interim-results.md0.58
  6. 2025-05-08Result OF Placing Related Parties Amp Tvr2025-05-08_8866548_result-of-placing-related-parties-amp-tvr.md0.46
  7. 2025-05-07Proposed Placing2025-05-07_8866204_proposed-placing.md0.46
  8. 2025-05-01Final Results For The Year Ended 30 November 20242025-05-01_8855707_final-results-for-the-year-ended-30-november-2024.md0.65
  9. 2025-01-24Trading Update2025-01-24_8703979_trading-update.md0.55
  10. 2024-12-02Disposal2024-12-02_8582911_disposal.md0.49
  11. 2024-07-08Interim Results2024-07-08_8297981_interim-results.md0.41
  12. 2024-05-24Final Results For The Year Ended 30 November 20232024-05-24_8219086_final-results-for-the-year-ended-30-november-2023.md0.45
  13. 2024-05-09Posting OF Notice OF Agm2024-05-09_8184254_posting-of-notice-of-agm.md0.14
  14. 2024-04-16Proposed Change OF Name2024-04-16_8138862_proposed-change-of-name.md0.27
  15. 2024-01-16Trading Update2024-01-16_7990488_trading-update.md0.38
  16. 2023-07-04Interim Results2023-07-04_7610860_interim-results.md0.23
  17. 2023-06-22Trading Update2023-06-22_7587575_trading-update.md0.21
  18. 2023-04-21Posting OF Notice OF Agm2023-04-21_1241_posting-of-notice-of-agm.md0.07
  19. 2023-04-21Posting OF Notice OF Agm2023-04-21_7494469_posting-of-notice-of-agm.md0.07
  20. 2023-04-17Final Results For The Year Ended 30 November 20222023-04-17_7491789_final-results-for-the-year-ended-30-november-2022.md0.25
  21. 2022-12-13Trading Update2022-12-13_7407002_trading-update.md0.21
  22. 2022-07-05Interim Results2022-07-05_6869820_interim-results.md0.23
  23. 2022-06-17Trading Update2022-06-17_6981689_trading-update.md0.21
  24. 2022-04-29Posting OF Notice OF Agm2022-04-29_7139502_posting-of-notice-of-agm.md0.07
  25. 2022-04-25Final Results For The Year Ended 30 November 20212022-04-25_7039599_final-results-for-the-year-ended-30-november-2021.md0.25
  26. 2022-01-17Trading Update2022-01-17_6856669_trading-update.md0.21
  27. 2021-09-02Completion OF Acquisition And RE Admission2021-09-02_6716930_completion-of-acquisition-and-re-admission.md0.07

This research note was authored by a large language model after reading 22 regulatory filings published between 2021-09-02 and 2026-07-20. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.